+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
ID07808879

Evaluation of 68GaGa-HBED-CC-PEG6-Exendin-4 Compared to 68GaGa-HBED-CC-Exendin-4 PETCT for Detecting Insulinoma in Adults

Led by Peking Union Medical College Hospital · Updated on 2026-09-09

20

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new PETCT imaging agent called 68GaGa-HBED-CC-PEG6-exendin-4 to locate insulinoma, a rare pancreatic tumor that causes severe low blood sugar. Insulinomas are often small and difficult to detect with standard imaging methods. This trial compares the new PEG6-modified tracer with an original similar tracer to see which better identifies insulinoma using PETCT scans. Participants will receive two PETCT scans within one week one with the new PEG6-modified tracer and one with the original tracer. The first three participants will also undergo dynamic PET scanning to study how the tracer behaves in the body and estimate radiation dose. After imaging, patients will have surgery or biopsy within 30 days to confirm tumor presence by pathology. During the trial, researchers collect medical history, lab tests, and prior imaging data before tracer injection. Two nuclear medicine physicians will analyze the scans without knowing which tracer was used to compare diagnostic accuracy. Participants are monitored for side effects from the injections and may withdraw anytime without penalty. All imaging costs are covered, and participants receive formal imaging reports for clinical use.

CONDITIONS

Brief Title

Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization

Research Team

Y

Yaping Luo, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here